DiaMedica Therapeutics Inc. (NASDAQ: DMAC) received a No Objection Letter from Health Canada to initiate a Phase 2 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE